Company profile

Akeso

9926 · HKEX

Public Market Listing

9926HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Akeso are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(10 total)
10Total Assets
0Approved
5Phase 3 / Filed
5Phase 1–2 / Early
5Diseases
Quick filter:
Showing 10 of 10 assets
Target & Modality
AK104
Phase 3
PD-1 x CTLA-4Multispecific antibody
Non-Small Cell Lung Cancer
EbronucimabNo recent activity
Phase 3
PCSK9Monoclonal antibody
Atherosclerotic Cardiovascular Disease
Ivonescimab
Phase 3
PD-1 + VEGFAMonoclonal antibody
Non-Small Cell Lung Cancer
Manfidokimab
Phase 3
IL-4R-alphaMonoclonal antibody
Atopic DermatitisAsthma
Penpulimab
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung Cancer
AK117
Phase 2
CD47
Acute Myeloid Leukemia
AK129
Phase 2
PD-1 and LAG-3Multispecific antibody
Non-Small Cell Lung Cancer
AK138D1
Phase 2
HER3Small molecule
Non-Small Cell Lung Cancer
AK139
Phase 2
IL-4 receptor alpha / ST2Multispecific antibody
Asthma
AK146D1
Phase 2
TROP2 / Nectin-4 (dual)Antibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.